Clinical Studies

  1. Slutsky I, Abumaria N, Wu LJ, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010;65(2):165-77.
  2. Liu G, Weinger JG, Lu ZL, et al. Efficacy and safety of MMFS-01, a synapse density enhancer, for treating cognitive impairment in older adults: a randomized, double-blind, placebo-controlled trial. J Alzheimers Dis. 2015;49(4):971-90.
  3. Mickley GA, Hoxha N, Luchsinger JL, et al. Chronic dietary magnesium-L-threonate speeds extinction and reduces spontaneous recovery of a conditioned taste aversion. Pharmacol Biochem Behav. 2013;106:16-26.
  4. Mahncke HW, Bronstone A, Merzenich MM. Brain plasticity and functional losses in the aged: scientific bases for a novel intervention. Prog Brain Res. 2006;157:81-109.
  5. Wang D, Jacobs SA, Tsien JZ. Targeting the NMDA receptor subunit NR2B for treating or preventing age-related memory decline. Expert Opin Ther Targets. 2014;18(10):1121-30.
  6. Abumaria N, Yin B, Zhang L, et al. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J Neurosci. 2011;31(42):14871-81.
  7. Basheer MP, Pradeep Kumar KM, Sreekumaran E, et al. A study of serum magnesium, calcium and phosphorus level, and cognition in the elderly population of South India. Alexandria J Med.
  8. Li W, Yu J, Liu Y, et al. Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer’s disease mouse model. J Neurosci. 2013;33(19):8423-41.
  9. Palacios-Prado N, Chapuis S, Panjkovich A, et al. Molecular determinants of magnesium-dependent synaptic plasticity at electrical synapses formed by connexin36. Nat Commun. 2014;5:4667.
  10. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry. 2003;18(Suppl 1):S23-32.
  11. Xu ZP, Li L, Bao J, et al. Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer’s model. PLoS One. 2014;9(9):e108645.
  12. Murphy T, Dias GP, Thuret S. Effects of diet on brai n plasticity in animal and human studies: mind the gap. Neural Plasticity. 2014;2014:32.
  13. Bilbo SD, Smith SH, Schwarz JM. A lifespan approach to neuroinflammatory and cognitive disorders: a critical role for glia. J Neuroimmune Pharmacol. 2012;7(1):24-41.
  14. Taniguchi R, Nakagawasai O, Tan-no K, et al. Combined low calcium and lack magnesium is a risk factor for motor deficit in mice. Biosci Biotechnol Biochem. 2013;77(2):266-70.
  15. Slutsky I, Sadeghpour S, Li B, et al. Enhancement of synaptic plasticity through chronically reduced Ca2+ flux during uncorrelated activity. Neuron. 2004;44(5):835-49.
  16. Li W, Yu J, Liu Y, et al. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model. Mol Brain. 2014;7:65.
  17. Yu J, Sun M, Chen Z, et al. Magnesium modulates amyloid-beta protein precursor trafficking and processing. J Alzheimers Dis. 2010;20(4):1091-106.
  18. Bisel BE, Henkins KM, Parfitt KD. Alzheimer amyloid beta-peptide A-beta25-35 blocks adenylate cyclase-mediated forms of hippocampal long-term potentiation. Ann N Y Acad Sci. 2007;1097:58-63.
  19. Yu X, Guan PP, Guo JW, et al. By suppressing the expression of anterior pharynx-defective-1alpha and -1beta and inhibiting the aggregation of beta-amyloid protein, magnesium ions inhibit the cognitive decline of amyloid precursor protein/presenilin 1 transgenic mice. Faseb j. 2015;29(12):5044-58.
  20. Chao LL, Tosun D, Woodward SH, et al. Preliminary evidence of increased hippocampal myelin content in veterans with posttraumatic stress disorder. Front Behav Neurosci. 2015;9:333.
  21. Cominski TP, Jiao X, Catuzzi JE, et al. The role of the hippocampus in avoidance learning and anxiety vulnerability. Front Behav Neurosci. 2014;8:273.
  22. Powers MB, Medina JL, Burns S, et al. Exercise augmentation of exposure therapy for PTSD: rationale and pilot efficacy data. Cogn Behav Ther. 2015;44(4):314-27.
  23. Wingo AP, Almli LM, Stevens JJ, et al. DICER1 and microRNA regulation in post-traumatic stress disorder with comorbid depression. Nat Commun. 2015;6:10106.
  24. Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443(7113):768-73.
  25. Grober U, Schmidt J, Kisters K. Magnesium in Prevention and Therapy. Nutrients. 2015;7(9):8199-226.
  26. Reynolds J, Hamill R D, Ellithorpe R., Settiner, R. Retarding cognitive decline with science-based nutraceuticals. The Journal of the American Nutraceutical Association. 2008;11 (1):19-27. (available online at
  27. Zhang JM, Hu GY. Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons. Neuroscience . 2001;105(3):663-9.
  28. Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer’s disease. Neurosignals . 2005;14 (1-2):71-82.
  29. Zhang, Z., Wang, X, Cheng, Q., Shu, L., Wang, J. & Shan, G. Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua yi xue za zhi. 2002; 82;941-944.
  30. Wang R, Zhang HY, Tang XC. Hupezine A attenuates cognitive dysfunction and neuronal degeneration caused by β-amyloid protein-(1-40) in rat. European Journal of Pharmacology. 2001; 421:149-156.
  31. Sun QQ, Xu SS, Pan JL, Guo HM, Cao WM. Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. ActaPharmacologica Sinica . 1999;20:601-603.
  32. Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, Zhang ML, Tong ZH, Fang YS, Chai XS, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer’s disease. Acta Pharmacologics Sinica . 1995;16 (3):391-395.
  33. Szatmari SZ, Whitehouse PJ..Vinpocetine for cognitive impairment and dementia. Cochrane database of systematic reviews (Online) ; 2003;
  34. Pereira C, Agostinho P, Moreira PI, Duarte AI, Santos MS, Oliveira CR. Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models. Acta Medica Portuguesa. 2003; 16(6):401-406.
  35. Dezs L, Kis-Varga I, Nagy J, Komlodi Z, Karpati E. Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke. Acta Pharmaceutica Hungarica. 2002; 72(2): 84-91.
  36. Santos MS, Duarte AI, Moreira PI , Oliveira CR. Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radical Research. 2000; 32(1):57-66.
  37. Vas A, Gulyas B. Eburnamine derivatives and the brain. Medicinal Research Reviews. 2005; 25(6): 737-757.
  38. Gulyas B, Halldin C, Sandell J, Karlsson P, Sovago J, Karpati E, Kiss B, Vas A. Cselenyi Z, Farde L. PET studies on the brain uptake and regional distribution of [11C] vinpocetine in human subjects. Acta Neurologica Scandanavica. 2002; 106(6):325-332. JANA Vol. 12, No. 1, 2009 19 Vas A, Gulyas B, Szabo Z, Bonoczk P, Csiba L, Kiss B, Karpati E, Panczel G, Nagy Z. Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences. Journal of Neurological Science. 2002; 203-204:259-262.
  39. Szakacs T, Veres Z, Vereczkey L. In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. Polish Journal of Pharmacology. 2001; 53(6):623-628. 16.Shibota M, Kakihana M, Nagaoka A. The effect of vinpocetine on brain glucose uptake in mice. Nippon yakurigaku zasshi. Folia pharmacologica Japonica. 1982; 80(3):221-224.
  40. Tohgi H, Sasaki K, Chiba K, Nozaki Y. Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimittel-Forschung. 1990; 40(6): 640-643.
  41. Polich J, Gloria R. Cognitive effects of a Ginkgo biloba/ vinpocetine compound in normal adults: Systematic assessment of perception, attention and memory. Human Psychopharmacology. 2001; 16; 409-416.
  42. Subhan, Z, Hindmarch I. Psychopharmacological effects of vinpocetine in normal healthy volunteers. European Journal of Clinical Pharmacology. 1985; 28: 567-571.
  43. Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Alternative medicine review: a journal of clinical therapeutic. 1999; 4(3):144-161.
  44. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Annals of New York and Academy of Science . 2004;1033: 30-41.
  45. Dhitavat S, Ortiz D, Shea TB, Riviera, ER. Acetyl-Lcarnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels. Neurochemical Research. 2002; 27(6): 501-505.
  46. Pettegrew JW, Levine J, McClure RJ. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression. Molecular Psychiatry. 2000; 5(6):616-632.
  47. Kalaria RN, Harick, SI. Carnitine acetyltransferase activity in the human brain and its microvessels is decreased in Alzheimer’s disease. Annals of Neurology. 1992; 32 (4): 583-586.
  48. Cavellini G, Caraciolo S, Vitali G, Modenini F, Biagiotti, G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004; 63(4): 641-646.
  49. Pettegrew JW, Levine J, Gershon S, Stanley JA, Servan-Schreiber D, Panchalingam K,McClure RJ. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disorders. 2002; 4(1): 61-66.
  50. Adriani W, Rea M, Baviera M. Invernizzi W, Carli M, Ghirardi O, Caprioli A, Laviola G. Acetyl-L-carnitine reduces impulsive behaviour in adolescent rats. Psychopharmacology. 2004;176(3-4): 296-304.
  51. Torrioli MG, Vernacotola S, Mariott,i P, Bianchi E, Calvani, M, De Gaetano A, Chiurazzi P, Neri G. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. American Journal of Medical Genetics. 1999; 87(4): 366-368.
  52. Tempesta, E. Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism. International Journal of Clinical Pharmacology Research. 1990; 10(1-2): 101-107.
  53. Mingrone G. Carnitine in type 2 diabetes. Annals of the New York Academy of Sciences. 2004; 1033: 99-107.
  54. Spryet LL, Dyck DJ, Cederbland G, Hultman, E. Effects of fat availability on acetyl-CoA and acetylcarnitine metabolism in rat skeletal muscle. American Journal of Physiology. 1992; 263(3 Pt 1): C653-659.
  55. Aureli T, Miccheli A, Di Cocco ME, Ghirardi O, Giuliani A, Ramacci MT, Conti F. Effect of acetyl-Lcarnitine on recovery of brain phosphorus metabolites and lactic acid level during reperfusion after cerebral ischemia in the rat-study by 13P- and 1H-NMR spectroscopy. Brain Research. 1994; 643(1-2): 92-99.
  56. White HL, Scates PW. Acetyl-L-carnitine as a precursor of acetylcholine. Neurochemical Research. 1990; 15(6): 597-601.
  57. Dolezal V, Tucek S. Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose for the synthesis of acetylcholine in rat brain slices. Journal of Neurochemistry. 1981; 36(4):1323-1330.
  58. Kido Y, Tamai I, Ohnari A, Sai Y, Kagami T, Nezu J, Nikaido H, Hashimoto N, Asano M, Tsuji A. Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. Journal of Neurochemistry. 2001; 79(5): 959-969.
  59. Rosadini G, Marenco S, Nobili F, Novellone G, Rodriguez, G. Acute effects of acetyl-L-carnitine on regional cerebral blood flow in patients with brain ischaemia. International Journal of Clinical Pharmacological Research. 1990; 10(1-2):123-128.
  60. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging.